Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 11/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.44 |
| ▸ | PPARG | P37231 | 4/20 | 0.40 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6433233 | 0.87 | ROCK2 (0.41) | ROCK2ROCK1PPARGTACR3 | |
| SCHEMBL7394132 | 0.86 | ROCK2 (0.49) | ROCK2ROCK1PPARGKDM4EGAA | |
| SCHEMBL6437559 | 0.83 | ROCK2 (0.38) | ROCK2KDM4EGAATAS1R3TAS1R1 | |
| SCHEMBL6435278 | 0.81 | ROCK2 (0.53) | ROCK2KDM4E | |
| SCHEMBL6435282 | 0.81 | ROCK2 (0.53) | ROCK2KDM4E | |
| SCHEMBL6434389 | 0.80 | PTPRC (0.49) | KDM4EGAA | |
| SCHEMBL6437307 | 0.78 | MAPT (0.43) | KDM4E | |
| SCHEMBL6436909 | 0.77 | DGAT2 (0.50) | — | |
| SCHEMBL6435819 | 0.76 | TAS1R3 (0.43) | TAS1R3TAS1R1 | |
| SCHEMBL6435824 | 0.76 | TAS1R3 (0.43) | TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1077945-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1242120-A2 | COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE | Pfizer Limited (GB) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001049309-A2 | COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE | PFIZER LIMITED (GB) | 2001-07-12 | — | — | WO | disclosed |
| EP-1077945-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6093731-A | Isoquinolines | PFIZER INC. | 2000-07-25 | — | — | US | disclosed |
| WO-2000005214-A2 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER INC. (US) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | ROCK2 2546/4885ROCK1 1845/4885PPARG 1104/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | ROCK2 2546/4885ROCK1 1845/4885PPARG 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.